Displaying 154 (all) recruiting clinical trials.
-
A Phase 1/2 Open-Label Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination with an anti-PD-1 Antibody in Patients with STK11-Mutated Advanced Solid Tumors
This is a first-in-human Phase 1/2, open-label, multicenter, dose-escalation and -expansion study designed to determine the MTD of TNG260 as single agent and in ... -
A Phase 1 Open-Label Multi-Center Safety and Efficacy Study of PRT3789 as Monotherapy and in Combination with Docetaxel in Participants with Select Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
The purpose of this first-in-human (FIH) study is to investigate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), maximum tolerated dose (MTD), recommended Phase 2 dose ... -
A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination with VS-6766 and Defactinib in Patients with Previously Untreated Metastatic Adenocarcinoma of the Pancreas
This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma ... -
A Single-Arm Phase 2 Study Of Daratumumab In Previously Treated Stk11/Lkb1 Mutated Non-Small Cell Lung Cancer
This is a single arm, signal finding study of daratumumab in metastatic NSCLC patients with an STK11/LKB1 mutation. Patients will have received previous standard ... -
A phase 1/1b/2 study evaluating the safety tolerability pharmacokinetics pharmacodynamics and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors
The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD ... -
A PHASE I/IB SINGLE ARM STUDY OF TWO FRACTION SBRT WITH DOMINANT LESION SIB FOR THE TREATMENT OF LOCALIZED PROSTATE CANCER
Phase I/IB, single arm trial of Two-Fraction SBRT with an MRI directed, dominant intraprostatic lesion, simultaneous integrated boost based on genomic classification in the ... -
Prospective Multicenter Single-Arm Study of Vanquish Water Vapor Ablation for PrOstate CanceR (VAPOR 2 Study)
The purpose of this study is to evaluate the safety and effectiveness of the Vanquish Water Vapor Ablation Device (“Vanquish”) in subjects with Gleason Grade ... -
I-SPY 2 TRIAL -Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2
The I-SPY 2.2 protocol uses the same strategy as the I-SPY 2.0 protocol to optimize response, measuring the impact of each therapeutic regimen ... -
A Phase 1b/2 Open-label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE)
This is a multicenter, Phase 1b/2 trial. The Phase 1b part of the trial aims to determine the RP2D of elacestrant when administered in ... -
Phase I open-label trial evaluating BI 1810631 as monotherapy in the treatment of patients with advanced or metastatic solid tumors with HER2 aberrations (BEAMION-Lung 1)
This is a Phase I, open-label, multicentre trial of BI 1810631 administered orally as a single agent. The trial has two parts; Phase Ia, which ...